Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice

Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wan, Tsuchiya, Kaoru, Kurosaki, Masayuki, Yasui, Yutaka, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Sekiguchi, Shuhei, Hayakawa, Yuka, Osawa, Leona, Okada, Mao, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Tamaki, Nobuharu, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Asahina, Yasuhiro, Enomoto, Nobuyuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826625/
https://www.ncbi.nlm.nih.gov/pubmed/31601010
http://dx.doi.org/10.3390/cancers11101517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826625/
https://www.ncbi.nlm.nih.gov/pubmed/31601010
http://dx.doi.org/10.3390/cancers11101517

Ejemplares similares